|Han-Soo Lee||Exec. Director of Fin. and Director||N/A||N/A||53|
|Mr. Seung-Kook Park Ph.D., M.B.A.||Head of Research, Exec. VP and Director||N/A||N/A||54|
|Mr. Seong-Jin Kim||Exec. Director of HR and Director||N/A||N/A||56|
Hanall Biopharma Co., Ltd., a pharmaceutical company, focuses on drug delivery, biotherapeutics, and new small molecules discovery worldwide. Its products under development include HL036, a TNF-alpha receptor fragment for the treatment of inflammatory diseases caused by TNF-alpha, such as uveitis, dry eyes, and AMD; and HL161, an anti-Fc neonatal receptor mAb for the treatment of autoimmune diseases caused by IgG autoantibodies and immune complex mediated glomerular diseases. The company also develops HL040, a combination of atorvastatin and losartan that completed Phase III clinical trial to treat hyperlipidemia and hypertension; HL063B, a combination of telmisartan and chlorthalidone, which is in Phase III clinical trial for hypertension; and HL068, a combination of amlodipine and candesartan that is in Phase III clinical trial to treat hypertension. In addition, it develops HL172, a combination of metformin HCl and candesartan; HL009, an adenosylcobalamin liposomal gel that has completed Phase II clinical trial for atopic dermatisis; HL018, a metformin acetate for obesity/DM2; HL143, a Hanferon that is in Phase II clinical trial for the prevention of postoperative HCC recurrence; and HL032, an oral Vitatropin for growth hormone deficiency. Hanall Biopharma Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.
HanAll Biopharma Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.